GlassScriptPhysician profile
Karla V Ow
NPI 1841614492
$2,688.17
in general payments reported to CMS, 2019-2025
19 companies · $992 in 2025
The $992 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $204 · 2022: $628 · 2023: $319 · 2024: $546 · 2025: $992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,696 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,695.98 |
| Education | $160.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $770.79 | 2021-2025 | Darzalex, Tecvayli, Carvykti |
| E.R. Squibb & Sons, L.L.C. | $239.41 | 2022-2024 | Reblozyl |
| Merck Sharp & Dohme LLC | $215.09 | 2025 | Keytruda |
| Celgene Corporation | $213.11 | 2022-2025 | Reblozyl, Breyanzi |
| Daiichi Sankyo INC. | $141.15 | 2025 | Datroway |
| Seagen INC. | $129.51 | 2021-2022 | |
| Eisai INC. | $122.28 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $121.86 | 2025 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $120.24 | 2023 | Imfinzi |
| Gilead Sciences, INC. | $112.44 | 2025 | Trodelvy |
| Incyte Corporation | $99.00 | 2022 | |
| Immunocore Limited | $90.86 | 2025 | Kimmtrak |
| Amgen INC. | $77.64 | 2021-2022 | |
| Legend Biotech USA INC. | $77.51 | 2022-2025 | Carvykti |
| Karyopharm Therapeutics INC. | $41.46 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $34.20 | 2023 | Krystexxa |
| Kite Pharma, INC. | $33.85 | 2024 | Yescarta |
| Morphosys, US INC. | $24.75 | 2021 | |
| Kyowa Kirin, INC. | $23.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Ow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.